The Analysis of The efficacy and risk factors in obesity with non-alcoholic fatty liver disease subjects treated with orlistat.

Chen Xi; Liang Bing; Wang YiGe; Fan XiaoHong

Issue 2

Feb. 2006

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2006 > 22(2): 123-124

PDF( 92 KB)

奥利司他对肥胖伴非酒精性脂肪性肝病的作用及危险因素的影响

Published Date: 2006-02-20

Abstract

Abstract

To evaluate the efficacy of orlistat in the treatment of obesity with non-alcoholic fatty liver disease.Orlistat 120mg, three times per day for a couse of 24 weeks, were given to the 30 cases non-alcoholic fatty liver disease (NAFLD) patients whose body mass index (BMI) were between 25 and 32.After 24 weeks treatment, mean weight、BMI、waist and waist/hip ratio (WHR) and blood pressure was significantly decreased (P<0.001) ;Liver functions (ALT、AST、GGT、TG and Tch) and IR was significantly decreased (P<0.001) ;The liver density value by CT scan and liver/spleen ratio by CT scan was significantly increased (P<0.001) .Orlistat can decrease the fat deposit on liver of NAFLD, improve the liver function and metabolic syndrome.It is a drug choice for obese patients with NAFLD.
- obesity,
- non-alcoholic fatty liver disease,
- orlistat

FullText(HTML)

【据Journal of Hepatology 2021年5月报道】题：急性病毒性肝炎的全球负担及其与社会经济发展状态的关系(1990年—2019年)(作者Zeng DY等)

急性病毒性肝炎(AVH)是全球重要的公共卫生健康问题，但由于全球病毒性肝炎防治重心在于后果严重的慢性乙型肝炎(CHB)以及慢性丙型肝炎(CHC)，而关于AVH的研究进展有限。随着最近针对病毒性肝炎的疫苗和治疗方法的进展，需要对AVH的负担进行更深入的了解，从而为全球干预策略提供依据。来自福建医科大学第一附属医院的Zeng等通过全球疾病负担2019数据库(Global Burden of Disease Study 2019)收集4种主要AVH类型的年龄标准化发病率和伤残调整生命年(DALY)率数据，包括A、B、C和E型急性肝炎，并将数据以性别、社会人口指数(SDI)水平、国家和地区进行分层，描述社会经济发展状态(以SDI为代表)与AVH负担的关联性。

2019年，全球4种主要AVH类型的年龄标准化发病率为3615.9(95%CI: 3 360.5~3 888.3)/10万人，年龄标准化DALY率为58.0(47.3~70.0)/10万人。其中，A型急性肝炎全球疾病负担最重。1990年—2019年，因上述4种AVH发病率下降，其年龄标准化DALY率呈现明显下降趋势。上述4种AVH在西非和中非地区及国家中年龄标准化发病率最高。SDI分层结果显示，高水平SDI和中高水平SDI地区的AVH发生率和DALY最低，而中低水平SDI和低水平SDI地区的AVH负担最高。

综上所述，AVH疾病负担与当地社会经济发展水平具有负相关性。因此，2019年全球疾病负担数据有利于决策者实施具有成本效益的AVH干预措施。

摘译自ZENG DY, LI JM, LIN S, et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019[J]. J Hepatol, 2021. DOI: 10.1016/j.jhep.2021.04.035. [Online ahead of print]

(福建医科大学附属第一医院肝病中心朱月永报道)

References(4)

References

[1]Marceau P, B iron S, Hou ld FS, et al.L iver pathology and the m eta-bolic syndrom e X in severe obesity[J].C lin Endoceinol M etab, 1999, 84∶1513-1517.

[2]Farrell GC.Non-alcoholic steatohepatitis:what is it, and why is itimportant in the Asia-Pacific region[J].Gastroenterol Hepatol, 2003, 18∶124-138.

[3]Tong PC, Lee ZS, Sea MM, et al.The effect of orlistat-inducedweight loss, w ithout concom itant hypocaloric d iet on card iovascu larrisk factors and insu lin sensitivity in young obese Ch inese sub jectsw ith or w ithout type 2 d iabetes[J].Arch Intern M ed, 2002, 162 (21) ∶2428-2435.

[4] Karen M, Hvizdos and Anthony.O rlistat.A review of its use in themanagem ent of obesity[J].D rug, 1999, 68 (4) ∶743-760.

Relative Articles

[1]	Aiping TIAN, Yongfeng YANG. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
[2]	Sutong LIU, Zhongjie YU, Wenxia ZHAO. Mechanism of action of traditional Chinese medicine in treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 458-462. doi: 10.3969/j.issn.1001-5256.2021.02.044
[3]	Shengnan DU, Jingjing GAO, Tao WANG, Yuanye JIANG, Qin CAO. Value of circular RNA in the diagnosis and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2684-2688. doi: 10.3969/j.issn.1001-5256.2021.11.043
[4]	Gao Xin. New thoughts about renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1201-1204. doi: 10.3969/j.issn.1001-5256.2020.06.001
[5]	A RuHan, Jia HaiYan, Ding YanHua, Niu JunQi. Research advances in nonalcoholic fatty liver disease in lean individuals[J]. Journal of Clinical Hepatology, 2020, 36(5): 1154-1159. doi: 10.3969/j.issn.1001-5256.2020.05.046
[6]	Li WenYi, Yuan ChengMin. Research advances in integrated traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 919-923. doi: 10.3969/j.issn.1001-5256.2020.04.047
[7]	YU Di, YANG XuYao, ZHAO JinHan, CHUAN LiXue, CHANG Jiang. Association between anxiety and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2589-2592. doi: 10.3969/j.issn.1001-5256.2020.11.043
[8]	WANG Xin, HU YiYang, LIU Ping, FENG Qin. Association between hypertension and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2584-2588. doi: 10.3969/j.issn.1001-5256.2020.11.042
[9]	Yang XuYao, Yu Di, Zhao JinHan, Chuan LiXue, Chang Jiang. Association between nonalcoholic fatty liver disease and depression[J]. Journal of Clinical Hepatology, 2020, 36(1): 201-204. doi: 10.3969/j.issn.1001-5256.2020.01.048
[10]	Ceng Jing, Fan JianGao. Clinical significance of renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1205-1207. doi: 10.3969/j.issn.1001-5256.2020.06.002
[11]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[12]	Jiang YuZi, Nie HongMing, Wang Rong. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(11): 2588-2591. doi: 10.3969/j.issn.1001-5256.2019.11.044
[13]	Gong Hang, Li LiangPing. Noninvasive diagnosis of progressive nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 406-410. doi: 10.3969/j.issn.1001-5256.2019.02.038
[14]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[15]	Cao HaiXia, Fan JianGao. Alcoholic liver disease with nonalcoholic fatty liver disease and obesity[J]. Journal of Clinical Hepatology, 2019, 35(3): 478-480. doi: 10.3969/j.issn.1001-5256.2019.03.005
[16]	Suo YuHong, Liu JinChun. Research advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2232-2236. doi: 10.3969/j.issn.1001-5256.2018.10.038
[17]	Xie Xiao, Lu LunGen. Potential therapeies for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2439-2443. doi: 10.3969/j.issn.1001-5256.2017.12.042
[18]	Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041
[19]	Liang Bing, Chen Xi, Liu ShuangYan, Wang YiGe, An QiuHong. The relationship between non-alcoholic fatty liver disease and insulin resistance[J]. Journal of Clinical Hepatology, 2006, 22(3): 213-214.
[20]	Ma YingJie, Fang LiFeng, Feng SuPing, Jia KeLi, Fu ZhenLie. Obesity and insulin resistance in nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2002, 18(4): 241-242.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2447) PDF downloads(974)

奥利司他对肥胖伴非酒精性脂肪性肝病的作用及危险因素的影响

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

奥利司他对肥胖伴非酒精性脂肪性肝病的作用及危险因素的影响

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content